Article and Video CATEGORIES
Dr. Benjamin Levy is a thoracic medical oncologist and the clinical director of medical oncology for the Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital, as well as an assistant professor of oncology for Johns Hopkins University School of Medicine. Dr. Levy is board certified in medical oncology and hematology by the American Board of Internal Medicine. He practices out of the Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital.
The 2021 Targeted Therapies Patient Forum, presented live-online, featured top oncologists in their field discussing the most current and emerging information in targeted therapies, and answering patient questions in real-time.
For the full agenda, visit https://cancergrace.org/2021-targeted-therapies-patient-forum-agenda, and for information on the faculty, https://cancergrace.org/2021-targeted-therapies-patient-forum-faculty.
For the full playlist of videos from the event, visit our YouTube channel! YOUTUBE PLAYLIST
A huge thank you to our sponsors! #AstraZeneca #Novartis #lilly #blueprintmedicines #takedaoncology #boehringerIngelheim #genentech
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Hello Linda, my name is Alexandra Beneke, I'm the Outreach Manager for GRACE. Your willingness to share your experiences and knowledge with the cancer community is truly inspiring. Your dedication to...
Recent Comments
That's…